139 related articles for article (PubMed ID: 12077913)
1. [The role of PET scan in the diagnosis of malignant melanoma].
Hunyadi J; Szakáll S; Gilde K; Bégány A; Esik O; Trón L; Galuska L; Ocsai H; Török L
Orv Hetil; 2002 May; 143(21 Suppl 3):1272-5. PubMed ID: 12077913
[TBL] [Abstract][Full Text] [Related]
2. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients.
Reinhardt MJ; Joe AY; Jaeger U; Huber A; Matthies A; Bucerius J; Roedel R; Strunk H; Bieber T; Biersack HJ; Tüting T
J Clin Oncol; 2006 Mar; 24(7):1178-87. PubMed ID: 16505438
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
Mruck S; Baum RP; Rinne D; Hör G
Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
[TBL] [Abstract][Full Text] [Related]
5. Detection of metastases in patients with cutaneous melanoma using FDG-PET/CT.
Akcali C; Zincirkeser S; Erbagcý Z; Akcali A; Halac M; Durak G; Sager S; Sahin E
J Int Med Res; 2007; 35(4):547-53. PubMed ID: 17697533
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of high-risk melanoma: comparison of [18F]FDG PET and high-dose 67Ga SPET.
Kalff V; Hicks RJ; Ware RE; Greer B; Binns DS; Hogg A
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):506-15. PubMed ID: 11914889
[TBL] [Abstract][Full Text] [Related]
7. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact.
Stas M; Stroobants S; Dupont P; Gysen M; Hoe LV; Garmyn M; Mortelmans L; Wever ID
Melanoma Res; 2002 Oct; 12(5):479-90. PubMed ID: 12394190
[TBL] [Abstract][Full Text] [Related]
8. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients.
Brady MS; Akhurst T; Spanknebel K; Hilton S; Gonen M; Patel A; Larson S
Ann Surg Oncol; 2006 Apr; 13(4):525-32. PubMed ID: 16474909
[TBL] [Abstract][Full Text] [Related]
9. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma.
Bastiaannet E; Uyl-de Groot CA; Brouwers AH; van der Jagt EJ; Hoekstra OS; Oyen W; Verzijlbergen F; van Ooijen B; Thompson JF; Hoekstra HJ
Ann Surg; 2012 Apr; 255(4):771-6. PubMed ID: 22367443
[TBL] [Abstract][Full Text] [Related]
11. Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma. Diagnostic comparison with conventional imaging methods.
Krug B; Dietlein M; Groth W; Stützer H; Psaras T; Gossmann A; Scheidhauer K; Schicha H; Lackner K
Acta Radiol; 2000 Sep; 41(5):446-52. PubMed ID: 11016764
[TBL] [Abstract][Full Text] [Related]
12. 18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma.
Kumar R; Xiu Y; Zhuang HM; Alavi A
Br J Dermatol; 2006 Aug; 155(2):357-63. PubMed ID: 16882175
[TBL] [Abstract][Full Text] [Related]
13. Interpretation, accuracy and management implications of FDG PET/CT in cutaneous malignant melanoma.
Falk MS; Truitt AK; Coakley FV; Kashani-Sabet M; Hawkins RA; Franc B
Nucl Med Commun; 2007 Apr; 28(4):273-80. PubMed ID: 17325590
[TBL] [Abstract][Full Text] [Related]
14. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
15. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma.
Crippa F; Leutner M; Belli F; Gallino F; Greco M; Pilotti S; Cascinelli N; Bombardieri E
J Nucl Med; 2000 Sep; 41(9):1491-4. PubMed ID: 10994727
[TBL] [Abstract][Full Text] [Related]
16. Malignant melanoma and (18)F-FDG-PET: Should the whole body scan include the legs?
Löffler M; Weckesser M; Franzius Ch; Nashan D; Schober O
Nuklearmedizin; 2003 Aug; 42(4):167-72. PubMed ID: 12937695
[TBL] [Abstract][Full Text] [Related]
17. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?
Tan JC; Chatterton BE
Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051
[TBL] [Abstract][Full Text] [Related]
18. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?
Fuster D; Chiang S; Johnson G; Schuchter LM; Zhuang H; Alavi A
J Nucl Med; 2004 Aug; 45(8):1323-7. PubMed ID: 15299056
[TBL] [Abstract][Full Text] [Related]
19. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma.
Acland KM; O'Doherty MJ; Russell-Jones R
J Am Acad Dermatol; 2000 Apr; 42(4):606-11. PubMed ID: 10727305
[TBL] [Abstract][Full Text] [Related]
20. Value of tumour marker S-100B in melanoma patients: a comparison to 18F-FDG PET and clinical data.
Reinhardt MJ; Kensy J; Frohmann JP; Willkomm P; Reinhold U; Grünwald F; Biersack HJ; Bender H
Nuklearmedizin; 2002 Jun; 41(3):143-7. PubMed ID: 12109034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
